SynthesisReviews in medical virology2026
Mpox Airborne Transmission: A Systematic Review.
Synthesis in Reviews in medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Since May 2022, mpox has been reported across multiple nonendemic regions, with concurrent outbreaks in diverse geographic settings, raising concerns about broader international spread. However, evidence regarding the risk of airborne transmission remains limited. We conducted a systematic review to evaluate the risk of airborne transmission and the presence of viable viruses in air samples. PubMed, Web of Science, and the Cochrane Library were searched for studies published in English, including environmental studies, case reports, cross-sectional studies, and cohort studies. Data extraction included study characteristics (authors, year, design, and setting), sample size, diagnostic methods, participant characteristics, follow-up, type of respiratory particles assessed (droplets and/or aerosols), and key findings. Of 286 records identified, four studies met the inclusion criteria. All were environmental studies published between 2022 and 2023. MPXV DNA was detected in surface and air samples, with cycle threshold (Ct) values ranging from < 30 to < 45. However, none of the studies demonstrated consistent viral viability in aerosols or droplets sufficient to support airborne transmission. Overall, the available evidence is limited and does not support a clear risk of airborne infection. Further well-designed studies in human settings are needed to clarify the potential for mpox transmission through respiratory routes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO: CRD42023391123.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.